BIS-Cyclic Guanidine Compounds as Novel Anti-Bacterial Agents

Competitive Advantages

  •     Low toxicity to human cells
  •     Potent anti-biofilm properties
  •     Effective against ESKAPE pathogens

Summary

By employing synthetic combinatorial libraries, our inventors have synthesized a class of bis-cyclic guanidine compounds that were found to have anti-bacterial activity against all six ESKAPE human pathogens. These compounds show promising efficacy in combating bacterial infections, while showing limited toxicity to human cells. The compounds exhibit potent anti-biofilm properties as well. 

Front runner bis-cyclic guanidines (red, blue, and green), are efficacious during in vivo infection. Mice were infected with a lethal dose of S. aureus and treated 1h post infection. 

Desired Partnerships

  • License
  • Sponsored Research
  • Co-development
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date
BIS-cyclic guanidine compound compositions, methods of use and treatment thereof Nationalized PCT United States 15/120,972 9,782,388 8/23/2016 10/10/2017 2/19/2035